Precision Dosing of Tacrolimus in Liver Transplantation: Integrating Donor-Recipient CYP3A5 Pharmacogenomics and Drug Interactions

CYP3A5

Apparent tacrolimus clearance modulated by the combined donor-recipient CYP3A5 genotype and by enzyme inhibition from fluconazole

Population pharmacokinetic analysis in 114 liver transplant recipients, yielding 1989 observations, with CYP3A5 genotyping of both recipients and donors. The authors formally compared linear elimination with Michaelis-Menten kinetics: a conventional two-compartment model described the data adequately without a saturable structure, the apparent non-linearity being captured by including daily dose as a covariate on clearance. The combined CYP3A5 genotype produced a stepwise reduction in apparent clearance from homozygous expressors to non-expressors. Fluconazole emerged as a major inhibitor, reducing clearance by 33%, while prednisolone showed modest induction and haemoglobin a significant inverse relationship. Monte Carlo simulations yielded substantially lower doses under fluconazole (1.5-3.0 mg every 12 h) than without it (2.5-7.0 mg every 12 h).

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The value of this work lies less in CYP3A5 itself, whose effect on tacrolimus has long been documented and is covered by a CPIC level A recommendation, than in the simultaneous handling of graft and recipient genotypes, and above all in quantifying the phenoconversion caused by fluconazole. A two-fold dose difference driven by antifungal co-prescription often exceeds the genotype effect itself: reasoning on CYP3A5 alone means ignoring a major share of the variability. The limitation is plain, these are simulations from a 114-patient cohort with a pharmacokinetic rather than clinical endpoint; the algorithm requires prospective validation on target attainment before routine use.

Analysis by Dr Thibaut Benquey